← Leaderboards
Susan Hedayati
Va North Texas Health Care System
$6,616,722
Attributed
$6,738,034
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,738,034 · 5
VA$0 · 1
By mechanism
R01$5,589,358 · 2
R38$668,301 · 1
R21$480,375 · 2
I01$0 · 1
Top collaborators
- Bethany Roehm2 shared
Others in their field
Top investigators on “Hospitalization”
- Larry Arthur$288,323,000
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$230,275,254
- Judith S. Currier · University Of California Los Angeles$223,149,861
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$221,207,102
- Lawrence Corey · Fred Hutchinson Cancer Center$217,829,567
- Daniel R Kuritzkes · Brigham And Women'S Hospital$179,610,394
Research focus
HospitalizationCessation Of LifeChronic Kidney FailurePharmaceutical PreparationsSertralineRandomizedDialysis ProcedureDouble-Blind MethodDepressive SymptomsPlacebosMental DepressionMajor Depressive DisorderSelective Serotonin Reuptake InhibitorInventory Of Depressive SymptomatologyAffectAntidepressive AgentsHigh PrevalenceQuality Of LifeFutureResearch PersonnelPatient PopulationRandomized TrialEnsureKidney
Grant awards (19)
Association between blood biomarkers and adverse cardiovascular and kidney outcomes$237,750
R21 · FY2025 · HL · contact PI
Combination of Novel Therapies for CKD Comorbid Depression (CONCORD)$595,152
R01 · FY2024 · DK · contact PI
Blood Biomarkers Associated with Adverse Outcomes in Heart Failure$119,625
R21 · FY2024 · HL · contact PI
Combination of Novel Therapies for CKD Comorbid Depression (CONCORD)$690,041
R01 · FY2023 · DK · contact PI
Blood Biomarkers Associated with Adverse Outcomes in Heart Failure$123,000
R21 · FY2023 · HL · contact PI
Combination of Novel Therapies for CKD Comorbid Depression (CONCORD)$693,788
R01 · FY2022 · DK · contact PI
Mechanisms for Behavior Change and Maintenance of Treatment for CKD Comorbid Depression$426,044
R01 · FY2022 · DK · contact PI
University of Texas Southwestern - Stimulating Access to Research in Residency (UT-StARR) Program$334,661
R38 · FY2022 · HL · contact PI
Combination of Novel Therapies for CKD Comorbid Depression (CONCORD)$696,929
R01 · FY2021 · DK · contact PI
University of Texas Southwestern - Stimulating Access to Research in Residency (UT-StARR) Program$333,640
R38 · FY2021 · HL · contact PI
Combination of Novel Therapies for CKD Comorbid Depression (CONCORD)$720,591
R01 · FY2020 · DK · contact PI
Randomized trial of sertraline treatment of depression in Chronic Kidney Disease$345,825
R01 · FY2015 · DK · contact PI
Randomized trial of sertraline treatment of depression in Chronic Kidney Disease$345,825
R01 · FY2014 · DK · contact PI
Randomized trial of sertraline treatment of depression in Chronic Kidney Disease$333,722
R01 · FY2013 · DK · contact PI
Randomized trial of sertraline treatment of depression in Chronic Kidney Disease$345,191
R01 · FY2012 · DK · contact PI
Randomized trial of sertraline treatment of depression in Chronic Kidney Disease$0
I01 · FY2012 · VA · contact PI
Randomized trial of sertraline treatment of depression in Chronic Kidney Disease$396,250
R01 · FY2011 · DK · contact PI
Randomized trial of sertraline treatment of depression in Chronic Kidney Disease$0
I01 · FY2011 · VA · contact PI
Randomized trial of sertraline treatment of depression in Chronic Kidney Disease$0
I01 · FY2009 · VA · contact PI